GlassScriptPhysician profile
Sangeeta Garg
NPI 1801874284
$7,067.16
in general payments reported to CMS, 2019-2025
30 companies · $1,463 in 2025
The $1,463 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $495 · 2021: $1,112 · 2022: $1,210 · 2023: $1,087 · 2024: $1,360 · 2025: $1,463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,878 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,878.12 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,210.39 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $1,054.76 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Diamondback Peripheral, Cardiomems |
| Astrazeneca Pharmaceuticals LP | $701.70 | 2020-2025 | Farxiga, Lynparza |
| Janssen Pharmaceuticals, INC | $554.93 | 2019-2023 | Xarelto |
| Amgen INC. | $521.09 | 2020-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $493.30 | 2020-2025 | |
| Alnylam Pharmaceuticals INC. | $410.17 | 2023-2025 | Amvuttra, Onpattro |
| Merck Sharp & Dohme LLC | $389.34 | 2022-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.61 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $217.06 | 2019-2023 | |
| Amarin Pharma, INC. | $195.43 | 2020-2023 | |
| Cvrx, INC. | $145.13 | 2023 | Barostim Neo System |
| Esperion Therapeutics, INC. | $140.59 | 2020-2025 | Nexletol |
| Boston Scientific Corporation | $123.83 | 2019-2023 | Watchman Flx, Watchman Access System |
| Pfizer INC. | $91.00 | 2020-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $70.71 | 2021-2023 | Arcalyst |
| Novo Nordisk INC | $68.46 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Scpharmaceuticals INC. | $59.08 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.27 | 2022-2025 | Lifevest |
| Abiomed | $38.69 | 2025 | |
| W. L. Gore & Associates, INC. | $36.28 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.03 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $31.52 | 2023-2024 | Inpefa |
| Atricure, INC. | $25.17 | 2024 | |
| Cleerly, INC. | $23.96 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Potrero Medical, INC. | $17.13 | 2023 | |
| Ionis Pharmaceuticals, INC. | $16.64 | 2025 | Tryngolza |
| Cashflow Solutions, LLC | $16.45 | 2025 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
| Arbor Pharmaceuticals, INC. | $14.17 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $13.27 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sangeeta Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.